Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management

International Journal of Antimicrobial Agents

Volumn 50, Issue 3, 2017, Pages 318-324

  Farmakiotis, Dimitrios ^a   Kontoyiannis, Dimitrios P ^b  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Candida; Candida auris; Candida glabrata; Resistance; Yeast

Indexed keywords

ECHINOCANDIN; POLYENE; PYRROLE; ANTIFUNGAL AGENT;

ANTIFUNGAL RESISTANCE; ARTICLE; CANDIDA; CANDIDA AURIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDIASIS; EPIDEMIC; HEALTH CARE FACILITY; HEMATOLOGIC MALIGNANCY; HOSPITAL INFECTION; HUMAN; KLUYVEROMYCES MARXIANUS; MULTIDRUG RESISTANCE; NONHUMAN; ONCOLOGY CENTER; PRIORITY JOURNAL; TERTIARY CARE CENTER; UNITED STATES; YEAST; ANTIMICROBIAL STEWARDSHIP; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOSIS; PREVALENCE; PROCEDURES;

ANTIFUNGAL AGENTS; ANTIMICROBIAL STEWARDSHIP; DRUG RESISTANCE, FUNGAL; HUMANS; MYCOSES; PREVALENCE; YEASTS;

EID: 85027461146     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.05.019     Document Type: Article

References (54)

1. Bassetti, M., Peghin, M., Timsit, J.F., The current treatment landscape: candidiasis. J Antimicrob Chemother 71:Suppl. 2 (2016), ii13–22.
2. Magill, S.S., Edwards, J.R., Bamberg, W., Beldavs, Z.G., Dumyati, G., Kainer, M.A., et al. Multistate point-prevalence survey of health care-associated infections. N Engl J Med 370 (2014), 1198–1208.
3. Wang, E., Farmakiotis, D., Yang, D., McCue, D.A., Kantarjian, H.M., Kontoyiannis, D.P., et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother 70 (2015), 2362–2368.
4. Farmakiotis, D., Kyvernitakis, A., Tarrand, J.J., Kontoyiannis, D.P., Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation. Clin Microbiol Infect 21 (2015), 79–86.
5. Jung, D.S., Farmakiotis, D., Jiang, Y., Tarrand, J.J., Kontoyiannis, D.P., Uncommon Candida species fungemia among cancer patients, Houston, Texas, USA. Emerg Infect Dis 21 (2015), 1942–1950.
6. Shields, R.K., Nguyen, M.H., Press, E.G., Kwa, A.L., Cheng, S., Du, C., et al. The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata. Antimicrob Agents Chemother 56 (2012), 4862–4869.
7. Alexander, B.D., Johnson, M.D., Pfeiffer, C.D., Jimenez-Ortigosa, C., Catania, J., Booker, R., et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56 (2013), 1724–1732.
8. Farmakiotis, D., Tarrand, J.J., Kontoyiannis, D.P., Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis 20 (2014), 1833–1840.
9. Vallabhaneni, S., Cleveland, A.A., Farley, M.M., Harrison, L.H., Schaffner, W., Beldavs, Z.G., et al. Epidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008–2014. Open Forum Infect Dis, 2, 2015, ofv163.
10. Beyda, N.D., John, J., Kilic, A., Alam, M.J., Lasco, T.M., Garey, K.W., FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 59 (2014), 819–825.
11. Bailly, S., Maubon, D., Fournier, P., Pelloux, H., Schwebel, C., Chapuis, C., et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp.—trends over 10 years. J Infect 72 (2016), 103–111.
12. Healey, K.R., Zhao, Y., Perez, W.B., Lockhart, S.R., Sobel, J.D., Farmakiotis, D., et al. Prevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistance. Nat Commun, 7, 2016, 11128.
13. Singh-Babak, S.D., Babak, T., Diezmann, S., Hill, J.A., Xie, J.L., Chen, Y.L., et al. Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. PLoS Pathog, 8, 2012 e1002718.
14. Pfaller, M.A., Castanheira, M., Lockhart, S.R., Ahlquist, A.M., Messer, S.A., Jones, R.N., Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50 (2012), 1199–1203.
15. Lortholary, O., Renaudat, C., Sitbon, K., Desnos-Ollivier, M., Bretagne, S., Dromer, F., et al. The risk and clinical outcome of candidemia depending on underlying malignancy. Intensive Care Med 43 (2017), 652–662.
16. Delliere, S., Healey, K., Gits-Muselli, M., Carrara, B., Barbaro, A., Guigue, N., et al. Fluconazole and echinocandin resistance of Candida glabrata correlates better with antifungal drug exposure rather than with MSH2 mutator genotype in a French cohort of patients harboring low rates of resistance. Front Microbiol, 7, 2016, 2038.
17. Wang, H., Xu, Y.C., Hsueh, P.R., Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region. Future Microbiol 11 (2016), 1461–1477.
18. Chapman, B., Slavin, M., Marriott, D., Halliday, C., Kidd, S., Arthur, I., et al. Changing epidemiology of candidaemia in Australia. J Antimicrob Chemother 72 (2017), 1103–1108.
19. Miyazaki, T., A single amino acid mutation in IPI1 confers multi-antifungal resistance without affecting virulence in Candida glabrata. 12th Annual American Society for Microbiology Conference on Candida and Candidiasis. 26–30 March 2016; New Orleans, LA, 2014, American Society for Microbiology, Washington, DC, 73.
20. Katiyar, S., Shiffrin, E., Shelton, C., Healey, K., Vermitsky, J.P., Edlind, T., Evaluation of polymorphic locus sequence typing for Candida glabrata epidemiology. J Clin Microbiol 54 (2016), 1042–1050.
21. Le, A., Kubiak, D., Koo, S., Farmakiotis, D., Epidemiology of candidemia in hospitalized patients with acute leukemia in the absence of routine antifungal prophylaxis. Open Forum Infect Dis, 3(Suppl. 1), 2016, 1597.
22. Fernandez-Ruiz, M., Aguado, J.M., Almirante, B., Lora-Pablos, D., Padilla, B., Puig-Asensio, M., et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis 58 (2014), 1413–1421.
23. Chiotos, K., Vendetti, N., Zaoutis, T.E., Baddley, J., Ostrosky-Zeichner, L., Pappas, P., et al. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12). J Antimicrob Chemother 71 (2016), 3536–3539.
24. Trouve, C., Blot, S., Hayette, M.P., Jonckheere, S., Patteet, S., Rodriguez-Villalobos, H., et al. Epidemiology and reporting of candidaemia in Belgium: a multi-centre study. Eur J Clin Microbiol Infect Dis 36 (2016), 649–655.
25. Xisto, M.I., Caramalho, R.D., Rocha, D.A., Ferreira-Pereira, A., Sartori, B., Barreto-Bergter, E., et al. Pan-azole-resistant Candida tropicalis carrying homozygous erg11 mutations at position K143R: a new emerging superbug?. J Antimicrob Chemother 72 (2017), 988–992.
26. Dufresne, S.F., Marr, K.A., Sydnor, E., Staab, J.F., Karp, J.E., Lu, K., et al. Epidemiology of Candida kefyr in patients with hematologic malignancies. J Clin Microbiol 52 (2014), 1830–1837.
27. Lortholary, O., Renaudat, C., Sitbon, K., Madec, Y., Denoeud-Ndam, L., Wolff, M., et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002–2010). Intensive Care Med 40 (2014), 1303–1312.
28. Taj-Aldeen, S.J., AbdulWahab, A., Kolecka, A., Deshmukh, A., Meis, J.F., Boekhout, T., Uncommon opportunistic yeast bloodstream infections from Qatar. Med Mycol 52 (2014), 552–556.
29. Forastiero, A., Garcia-Gil, V., Rivero-Menendez, O., Garcia-Rubio, R., Monteiro, M.C., Alastruey-Izquierdo, A., et al. Rapid development of Candida krusei echinocandin resistance during caspofungin therapy. Antimicrob Agents Chemother 59 (2015), 6975–6982.
30. Ben-Ami, R., Berman, J., Novikov, A., Bash, E., Shachor-Meyouhas, Y., Zakin, S., et al. Multidrug-resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis, 23, 2017, 10.3201/eid2302.161486.
31. Asner, S.A., Giulieri, S., Diezi, M., Marchetti, O., Sanglard, D., Acquired multidrug antifungal resistance in Candida lusitaniae during therapy. Antimicrob Agents Chemother 59 (2015), 7715–7722.
32. Espinel-Ingroff, A., Arendrup, M.C., Pfaller, M.A., Bonfietti, L.X., Bustamante, B., Canton, E., et al. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?. Antimicrob Agents Chemother 57 (2013), 5836–5842.
33. Vallabhaneni, S., Kallen, A., Tsay, S., Chow, N., Welsh, R., Kerins, J., et al. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. Am J Transplant 17 (2017), 296–299.
34. Calvo, B., Melo, A.S., Perozo-Mena, A., Hernandez, M., Francisco, E.C., Hagen, F., et al. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect 73 (2016), 369–374.
35. Schelenz, S., Hagen, F., Rhodes, J.L., Abdolrasouli, A., Chowdhary, A., Hall, A., et al. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control, 5, 2016, 35.
36. Mizusawa, M., Miller, H., Green, R., Lee, R., Durante, M., Perkins, R., et al. Can multidrug-resistant Candida auris be reliably identified in clinical microbiology laboratories?. J Clin Microbiol 55 (2017), 638–640.
37. Arendrup, M.C., Prakash, A., Meletiadis, J., Sharma, C., Chowdhary, A., Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother, 61, 2017 pii: e00485-17.
38. Larkin, E., Hager, C., Chandra, J., Mukherjee, P.K., Retuerto, M., Salem, I., et al. The emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation. Antimicrob Agents Chemother, 61, 2017 pii: e02396-16.
39. Morales-Lopez, S.E., Parra-Giraldo, C.M., Ceballos-Garzon, A., Martinez, H.P., Rodriguez, G.J., Alvarez-Moreno, C.A., et al. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis 23 (2017), 162–164.
40. Rudramurthy, S.M., Chakrabarti, A., Paul, R.A., Sood, P., Kaur, H., Capoor, M.R., et al. Candida auris candidaemia in Indian ICUs: analysis of risk factors. J Antimicrob Chemother 72 (2017), 1794–1801.
41. Lockhart, S.R., Etienne, K.A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N.P., et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64 (2017), 134–140.
42. Prakash, A., Sharma, C., Singh, A., Kumar Singh, P., Kumar, A., Hagen, F., et al. Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clin Microbiol Infect, 22, 2016, 277 e1–9.
43. Borman, A.M., Szekely, A., Johnson, E.M., Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere, 1, 2016 pii: e00189–16.
44. Miceli, M.H., Diaz, J.A., Lee, S.A., Emerging opportunistic yeast infections. Lancet Infect Dis 11 (2011), 142–151.
45. Chitasombat, M.N., Kofteridis, D.P., Jiang, Y., Tarrand, J., Lewis, R.E., Kontoyiannis, D.P., Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect 64 (2012), 68–75.
46. Fernández-Ruiz, M., Guinea, J., Puig-Asensio, M., Zaragoza, Ó., Almirante, B., Cuenca-Estrella, M., et al. Fungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain. Med Mycol 55 (2017), 125–136.
47. Bretagne, S., Renaudat, C., Desnos-Ollivier, M., Sitbon, K., Lortholary, O., Dromer, F., et al. Predisposing factors and outcome of uncommon yeast species-related fungaemia based on an exhaustive surveillance programme (2002–14). J Antimicrob Chemother 72 (2017), 1784–1793.
48. Shields, R.K., Nguyen, M.H., Press, E.G., Clancy, C.J., Abdominal candidiasis is a hidden reservoir of echinocandin resistance. Antimicrob Agents Chemother 58 (2014), 7601–7605.
49. Zhao, Y., Nagasaki, Y., Kordalewska, M., Press, E.G., Shields, R.K., Nguyen, M.H., et al. Rapid detection of FKS-associated echinocandin resistance in Candida glabrata. Antimicrob Agents Chemother 60 (2016), 6573–6577.
50. Seyedmousavi, S., Rafati, H., Ilkit, M., Tolooe, A., Hedayati, M.T., Verweij, P., Systemic antifungal agents: current status and projected future developments. Methods Mol Biol 1508 (2017), 107–139.
51. Hamdy, R.F., Zaoutis, T.E., Seo, S.K., Antifungal stewardship considerations for adults and pediatrics. Virulence, 2016, 1–15.
52. Tang, H.J., Liu, W.L., Lin, H.L., Lai, C.C., Epidemiology and prognostic factors of candidemia in cancer patients. PLoS ONE, 9, 2014 e99103.
53. Fekkar, A., Dannaoui, E., Meyer, I., Imbert, S., Brossas, J.Y., Uzunov, M., et al. Emergence of echinocandin-resistant Candida spp. in a hospital setting: a consequence of 10 years of increasing use of antifungal therapy?. Eur J Clin Microbiol Infect Dis 33 (2014), 1489–1496.
54. Barlam, T.F., Cosgrove, S.E., Abbo, L.M., MacDougall, C., Schuetz, A.N., Septimus, E.J., et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62 (2016), e51–77.